Drug intelligence / Profile preview

SR-017

Development stage: Preclinical
Lead developer: Surrozen

Overview

SR-017 is a lead candidate drug developed by Surrozen, a clinical-stage biotechnology company. It is a novel therapeutic targeting the Wnt signaling pathway, intended for the treatment of osteoporosis. The drug's development is supported by capital raised through a business combination agreement between Surrozen and Consonance-HFW Acquisition Corp., a SPAC, which allowed Surrozen to become a public company.

Targets

FZD (Frizzled receptor family)LRP5 (Low-density lipoprotein receptor-related protein 5)

Beyond the preview

Go deeper on SR-017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR-017.

Explore the full profile